Clinical Trials Sponsored by Alizyme

Total 88 results

Alizyme

Terminated

Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)

Constipation-Predominant Irritable Bowel Syndrome

United States
Alizyme

Completed

Study of COLAL-PRED® in the Treatment of Moderate Acute Ulcerative Colitis

Ulcerative Colitis

Spain, Belgium, Denmark, United Kingdom, South Africa, Israel, France, Australia, Sweden, Italy, Poland, Czech Republic, Germany, Hungary, Russian Federation
Alizyme

Completed

Investigation of the Safety and Efficacy of Renzapride in Constipation Predominant Irritable Bowel Syndrome (IBS)

Irritable Bowel Syndrome

United Kingdom
Alizyme

Completed

Safety, Tolerability and Efficacy of ATL-104 in Oral Mucositis

Mucositis

United Kingdom
Alizyme

Completed

Efficacy and Safety of ATL-962 in Obese Diabetics

Obesity | Non-Insulin-Dependent Diabetes Mellitus

Finland, Netherlands, Denmark, United Kingdom, Sweden
Alizyme

Completed

Study of the Blood Levels and Effects of ATL-962 on Fat Excretion in Obese Subjects

Obesity

United States
Halozyme Therapeutics

Completed

PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer

Metastatic Pancreatic Cancer

United States
Halozyme Therapeutics

Completed

Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

United States
Halozyme Therapeutics

Completed

CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)

Type 1 Diabetes Mellitus

United States
Halozyme Therapeutics

Completed

Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)

Diabetes Mellitus, Type 2

United States
Halozyme Therapeutics

Completed

A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs Alone

Healthy

United States
Halozyme Therapeutics

Completed

Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors

Solid Tumor

United States
Halozyme Therapeutics

Completed

INFUSE Morphine Study (INFUSE)

Pain

United States
Epizyme, Inc.

Completed

Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma

Mesothelioma | BAP1 Loss of Function

United States, United Kingdom, France
Halozyme Therapeutics

Terminated

A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

Pancreatic Ductal Carcinoma

Korea, Republic of, United States, Taiwan, United Kingdom, Israel, France, Germany, Netherlands, Canada, Spain, Australia, Brazil, Belgium, Croatia, Czechia, Denmark, Estonia, Hungary, Italy, Latvia, Lithuania, Poland
Halozyme Therapeutics

Completed

A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors

Gastric Cancer | NSCLC

United States
Halozyme Therapeutics

Completed

Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20

Diabetes Mellitus

United States
Halozyme Therapeutics

Completed

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

United States
Halozyme Therapeutics

Completed

Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase

Type 1 Diabetes Mellitus

United States
Halozyme Therapeutics

Completed

Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20

Healthy Volunteers

United States
Halozyme Therapeutics

Completed

Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

United States
Halozyme Therapeutics

Completed

Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers

Healthy

United States
Halozyme Therapeutics

Completed

Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors (PEG)

Solid Tumor

United States
Halozyme Therapeutics

Completed

A Study of the Subcutaneous Injection of a Viscous Antibody Solution With Recombinant Human Hyaluronidase

Healthy
Halozyme Therapeutics

Completed

A Phase IIIB Dose Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase (HYLENEX) in Volunteer Subjects

Healthy

United States
Epizyme, Inc.

Completed

A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

Synovial Sarcoma | INI1-negative Tumors | Malignant Rhabdoid Tumor of Ovary | Rhabdoid Tumors

United States, France, Canada, Italy, Germany, United Kingdom, Australia, Denmark, Netherlands
Halozyme Therapeutics

Completed

Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis

Dermatitis, Allergic Contact

United States
Halozyme Therapeutics

Completed

Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer

Bladder Cancer

United States
Halozyme Therapeutics

Terminated

Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Cholangiocarcinoma Non-resectable | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinoma, Intrahepatic | Gallbladder Adenocarcinoma

United States, Korea, Republic of, Thailand
Halozyme Therapeutics

Terminated

A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC (PRIMAL)

Non-small Cell Lung Cancer

United States
Halozyme Therapeutics

Completed

A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20) (HALO-117-406)

Type 1 Diabetes Mellitus

United States
Halozyme Therapeutics

Completed

Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer

Stage IV Pancreatic Cancer

United States, Russian Federation
Halozyme Therapeutics

Completed

Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate Alone

Risk Factors for or a Diagnosis of Osteoporosis

United States
Halozyme Therapeutics

Completed

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type II

United States
Halozyme Therapeutics

Completed

Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)

Type 1 Diabetes Mellitus

United States
Halozyme Therapeutics

Completed

Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone

Diabetes Mellitus

United States
Halozyme Therapeutics

Completed

Study of Immediate Post-Operative Intravesical Instillation of Chemophase® in Patients With Superficial Bladder Cancer (IPOP)

Superficial Bladder Cancer

United States
Halozyme Therapeutics

Completed

Study of a Large Protein Molecule Administered With Escalating Doses of Recombinant Human Hyaluronidase

Rheumatoid Arthritis
Epizyme, Inc.

Recruiting

A Study of the Safety, Tolerability and Effectiveness of EZM0414 Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma

Diffuse Large B-Cell Lymphoma | Diffuse Large B Cell Lymphoma Refractory | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

United States
Epizyme, Inc.

Recruiting

Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma

Advanced Soft-tissue Sarcoma | Advanced Epithelioid Sarcoma

United States, Taiwan, Canada, United Kingdom
Epizyme, Inc.
Ipsen

Not yet recruiting

A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation (Mandolin)

Follicular Lymphoma | Refractory Follicular Lymphoma
Epizyme, Inc.

Completed

Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL

B-cell Lymphomas (Phase 1) | Advanced Solid Tumors (Phase 1) | Diffuse Large B-cell Lymphoma (Phase 2) | Follicular Lymphoma (Phase 2) | Transformed Follicular Lymphoma | Primary Mediastinal Large B-Cell Lymphoma

Australia, Canada, France, Germany, Italy, Poland, Taiwan, Ukraine, United Kingdom, United States
Epizyme, Inc.

No longer available

Tazemetostat Expanded Access Program for Adults With Solid Tumors

Renal Cell Carcinoma | Malignant Mesothelioma | Chondrosarcoma | Synovial Sarcoma | Renal Medullary Carcinoma | Malignant Rhabdoid Tumor | Poorly Differentiated Chordoma | Malignant Rhabdoid Tumor of Ovary | Epithelioid Malignant Peripheral Nerve Sheath Tumor | Sinonasal Carcinoma | Spindle Cell Sarcoma | Epithelioid... and other conditions
Epizyme, Inc.

Completed

Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors

Follicular Lymphoma | Marginal Zone Lymphoma | Advanced Solid Tumors | Mantle-Cell Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal Lymphoma

United Kingdom
Epizyme, Inc.

Completed

Study to Describe the Interaction Between Tazemetostat and Itraconazole and Between Tazemetostat and Rifampin in Participants With Advanced Cancer

Solid Tumor | Mesothelioma | Rhabdoid Tumor | Hematologic Malignancy | Advanced Malignancies | Synovial Sarcoma | Renal Medullary Carcinoma | Diffuse Large B-Cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Non-Hodgkin Lymphoma (NHL) | All Malignancies | Epithelioid Sarcoma (ES)

Spain, United States
Pfizer
Halozyme Therapeutics

Terminated

Pharmacokinetic and Pharmacodynamic Study of Bococizumab Alone and When Combined With Recombinant Human Hyaluronidase

Healthy | Hypercholesterolemia

Belgium
Epizyme, Inc.

Recruiting

Study of Tazemetostat Versus Placebo When Given in Combination With Lenalidomide and Rituximab in Participants With Relapsed/Refractory Follicular Lymphoma (SYMPHONY-1)

Follicular Lymphoma | Relapsed/Refractory Follicular Lymphoma | Refractory Follicular Lymphoma

United States, China, Spain, France, Taiwan, United Kingdom, Australia, Korea, Republic of, Canada, Italy, Hungary, Poland, Belgium, Germany
Epizyme, Inc.

Active, not recruiting

A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma

Synovial Sarcoma | Epithelioid Sarcoma | Renal Medullary Carcinoma | Malignant Rhabdoid Tumors (MRT) | Rhabdoid Tumors of the Kidney (RTK) | Atypical Teratoid Rhabdoid Tumors (ATRT) | Selected Tumors With Rhabdoid Features | INI1-negative Tumors | Malignant Rhabdoid Tumor of Ovary | Poorly Differentiated... and other conditions

France, United States, Australia, Taiwan, Belgium, United Kingdom, Canada, Germany, Italy
Epizyme, Inc.

Enrolling by invitation

A Study to Assess the Long-term Safety of Tazemetostat (TRuST)

Advanced Solid Tumors | Mesothelioma | Synovial Sarcoma | Renal Medullary Carcinoma | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Non-Hodgkin Lymphoma (NHL) | Epitheliod Sarcoma (ES)

United States, France, United Kingdom, Poland, Australia, Belgium, Ukraine
Epizyme, Inc.

Active, not recruiting

A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer (CELLO-1)

Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States, Spain, Belgium

3

Subscribe